

Press release

Migco Pharmaceuticals To Present at 7th Annual BioPartnering North America (BPN) Conference, Vancouver, Canada

Rangiora, New Zealand -17 December 2008- Migco Pharmaceuticals Ltd, a drug development company focused on bringing to market innovative new products that will significantly improve the lives of those suffering from migraine headache, announced today that it will be presenting at the Annual BioPartnering North America Conference in Vancouver, Canada. The BPN Conference is taking place February 8-10, 2009.

Mr Larry Stenswick, CEO of Migco Pharmaceuticals, will give a podium presentation focused on the latest developments of its lead compound , MGX-008, and Migco's natural advantages in drug development.

The presentation will be held at the Westin Bayshore Resort and Marina on Tuesday, February 10 at 10:30 am in the Cowichan Room.

About BioPartnering North America

BioPartnering North America (BPN) brings together decision-makers from leading biotechnology, pharmaceutical and investment companies and features company presentations, partnering meetings, expert panels and workshops.

About Migco Pharmaceuticals

Founded by Larry Stenswick, the company's Chief Executive Officer in 2004, Migco Pharmaceuticals is progressing Migco's lead compound, MGX-008, toward approval as a prescription medicine. Based on a novel class of botanical therapeutic compounds, MGX-008 represents a new approach to migraine prevention and treatment. Opportunities are also emerging for the treatment of other neurological conditions including ADHD and Alzheimers. Migco is working closely with research collaborators in the United States, Australia, the United Kingdom and India. Its wholly owned subsidiary MigcoBio Pty Ltd, based in Queensland Australia, is developing complimentary gene based solutions for the diagnoses and treatment of migraine.

Contacts

Larry Stenswick :

Ph + 64 3 313 8284

Fax + 64 3 313 8961

Mobile + 64 21 755 900

stenswick@migco.co.nz

www.migco.co.nz